Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings. (2023)

First Author: Readman JB
Attributed to:  Mathematical and Statistical Modelling to Optimise Paediatric Medicines Research funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkad177

PubMed Identifier: 37283195

Publication URI: http://europepmc.org/abstract/MED/37283195

Type: Journal Article/Review

Volume: 78

Parent Publication: The Journal of antimicrobial chemotherapy

Issue: 8

ISSN: 0305-7453